Fidaxomicin is a recently Food and Drug Administration–approved oral medication for the treatment of Clostridium difficile infection. This medication is typically reserved for patients who have failed therapy with oral metronidazole. Here we present a case of a 79-year-old man with recurrent C. difficile infection who developed pitting lower extremity edema and a confluent, purpuric drug eruption 3 days into treatment with fidaxomicin. The rash improved completely with cessation of the medication. To our knowledge, this is the first report of a purpuric drug eruption secondary to fidaxomicin.